Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)). Reference standards of Cerdulatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Cerdulatinib
Catalogue No.:PA 03 3830000
CAS :
Molecular Formula : C20H27N7O3S
Molecular Weight : 445.54
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
